IL1B and hydrops fetalis: Emerging therapeutic options for CMD include nonsteroidal anti-inflammatory drugs such as colchicine and interleukin-1 (IL-1) blockers, which may prevent endothelial inflammation and reduce the risk of HF and stroke.